SCNX (Scienture Holdings) YoY EBITDA Growth: 87.62% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNX Scienture Holdings Inc SCNX
45 GF Score
Price $0.39
GF Value $0.52
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Scienture Holdings YoY EBITDA Growth?

Scienture Holdings SCNX -1.40% 45 YoY EBITDA Growth is 87.62% as of Jun. 2026. GuruFocus rates SCNX with a GF Score™ of 45/100 and a GF Value™ of $0.52 (Modestly Undervalued). The stock has 9 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scienture Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 87.62%.

Scienture Holdings's EBITDA per Share for the three months ended in Jun. 2026 was $-0.05.

Scienture Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Scienture Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scienture Holdings YoY EBITDA Growth Chart

Scienture Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -103.27 65.26 20.01 -80.13 46.69

Scienture Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.65 92.34 -114.29 71.83 87.62
SCNX
45GF Score
Scienture Holdings Inc SCNX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scienture Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scienture Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-2.537--4.759)/ | -4.759 |
=46.69 %

Scienture Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.053--0.428)/ | -0.428 |
=87.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 87.62% mean?
Scienture Holdings (SCNX) has a YoY EBITDA Growth of 87.62% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scienture Holdings and its competitors.
Is Scienture Holdings' YoY EBITDA Growth too high?
Scienture Holdings' current YoY EBITDA Growth is 87.62%. Overall, Scienture Holdings has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' YoY EBITDA Growth compare to PMHS and HEWA?
Scienture Holdings' YoY EBITDA Growth of 87.62% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Scienture Holdings and its competitors. Scienture Holdings's current YoY EBITDA Growth is 87.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.39 — trading 25.3% below its estimated fair value. The current YoY EBITDA Growth is 87.62%. Scienture Holdings' overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current YoY EBITDA Growth is 87.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scienture Holdings (SCNX) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued. The current stock price of $0.39 is trading 25.3% below its estimated GF Value™ of $0.52. GuruFocus considers Scienture Holdings to be Modestly Undervalued.

Key valuation signals for SCNX:

  • YoY EBITDA Growth: 87.62%
  • GF Value™: $0.52 vs. price of $0.39 (25.3% below fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scienture Holdings Business Description

Other Exchanges 4E4:Germany
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
45GF Score

Get the complete analysis for SCNX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$0.52
GF Value